Long-term comparison of laparoscopy-assisted distal gastrectomy and open distal gastrectomy in advanced gastric cancer

2012 ◽  
Vol 27 (2) ◽  
pp. 462-470 ◽  
Author(s):  
Andrew C. Gordon ◽  
Kazuyuki Kojima ◽  
Mikito Inokuchi ◽  
Keiji Kato ◽  
Kenichi Sugihara
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Distal Gastrectomy ◽  
Open Distal Gastrectomy

scholarly journals Oncologic outcomes after laparoscopic and open distal gastrectomy for advanced gastric cancer: A propensity score matching analysis.

2019 ◽  
Vol 37 (4_suppl) ◽  
pp. 135-135
Author(s):  
Yoona Chung ◽  
Sung Il Choi ◽  
Kyungpyo Hong ◽  
Sanghyun Kim
Keyword(s):  
Gastric Cancer ◽  
Propensity Score ◽  
Advanced Gastric Cancer ◽  
Propensity Score Matching ◽  
Distal Gastrectomy ◽  
Laparoscopic Distal Gastrectomy ◽  
Oncologic Outcomes ◽  
Open Distal Gastrectomy ◽  
Propensity Score Matching Analysis

135 Background: The aim of this study is to investigate the oncologic outcomes as well as short-term outcomes of laparoscopic distal gastrectomy compared with open distal gastrectomy for advanced gastric cancer using propensity-score matching analysis. Methods: A total of 384 patients underwent distal gastrectomy for advanced gastric cancer from July 2006 to November 2016. Data on short- and long-term outcomes were collected prospectively and reviewed. Propensity-score matching was applied at a ratio of 1:1 comparing the laparoscopic distal gastrectomy (LDG) group and open distal gastrectomy (ODG) groups. Results: The LDG group showed longer operative time than the ODG group. However, resumption of diet and length of hospital stay were shorter in the LDG group than in the ODG group (4.7 vs. 5.6 days, p= 0.049 and 9.6 vs. 11.5 days, p= 0.035, respectively).The extent of lymph node dissection in the LDG group was more limited than in the ODG group ( p= 0.002), although there was no difference in the number of retrieved lymph nodes between the two groups. The 3-year overall survival rates were 98% and 86.9% ( p= 0.018), whereas the 3-year recurrence-free survival were 86.3% and 75.3%, p= 0.259) in the LDG and the ODG groups. Conclusions: Laparoscopic distal gastrectomy is safe and feasible for advanced gastric cancer in terms of earlier recovery after surgery and long-term oncologic outcomes.

scholarly journals Laparoscopic Versus Open Distal Gastrectomy With D2 Lymph Node Dissection for cT2 Gastric Cancer: A Retrospective Cohort Study of Short- and Long-Term Outcomes

2015 ◽  
Vol 100 (9-10) ◽  
pp. 1315-1322 ◽  
Author(s):  
Kei Hosoda ◽  
Shinichi Sakuramoto ◽  
Natsuya Katada ◽  
Keishi Yamashita ◽  
Hiromitsu Moriya ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Distal Gastrectomy ◽  
Survival Rates ◽  
Controlled Study ◽  
D2 Lymphadenectomy ◽  
Open Distal Gastrectomy ◽  
Long Term Outcomes ◽  
Relapse Free Survival ◽  
Free Survival

The purpose of this study was to determine whether laparoscopy-assisted distal gastrectomy (LDG) with D2 lymphadenectomy could be a standard treatment for cT2N0-1 gastric cancer. There have been few reports regarding the long-term outcomes of patients with advanced gastric cancer who underwent LDG with D2 lymphadenectomy. The study included 32 patients who underwent LDG with D2 lymphadenectomy and 44 patients who underwent open distal gastrectomy (ODG) with D2 lymphadenectomy. There was no clinicopathologic difference in patient background between the groups. Operative duration was significantly longer in the LDG group than in the ODG group (297 ± 12 minutes versus 226 ± 10 minutes; P < 0.001). However, blood loss was significantly less (90 ± 27 mL versus 314 ± 23 mL; P < 0.001) and the number of days to assisted ambulation significantly shorter (1.1 ± 0.1 days versus 1.5 ± 0.1 days; P = 0.010) in the LDG group than in the ODG group. Median follow-up period was 60 months. The 5-year overall survival rates for the LDG group and the ODG group were 89.5% and 97.1%, respectively. The 5-year relapse-free survival rates for the LDG group and the ODG group were 88.0% and 97.7%, respectively. There were no significant differences in overall and relapse-free survival rates between the groups. LDG with D2 lymphadenectomy for cT2N0-1 gastric cancer is oncologically and technically safe and feasible, and is an option in the surgeon's arsenal. Randomized controlled study including the investigation of cost-effectiveness should be conducted.

Laparoscopic versus open distal gastrectomy for locally advanced gastric cancer: a case–control study

2011 ◽  
Vol 63 (1) ◽  
pp. 17-23 ◽  
Author(s):  
Marco Scatizzi ◽  
Katrin C. Kröning ◽  
Elisa Lenzi ◽  
Luca Moraldi ◽  
Stefano Cantafio ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Case Control Study ◽  
Distal Gastrectomy ◽  
Locally Advanced ◽  
Case Control ◽  
Open Distal Gastrectomy ◽  
Locally Advanced Gastric Cancer ◽  
Control Study

scholarly journals Laparoscopic or open distal gastrectomy after neoadjuvant chemotherapy for advanced gastric cancer: study protocol for a randomised phase II trial

BMJ Open ◽  
2018 ◽  
Vol 8 (8) ◽  
pp. e021633 ◽  
Author(s):  
Ziyu Li ◽  
Fei Shan ◽  
Xiangji Ying ◽  
Lianhai Zhang ◽  
Hui Ren ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Advanced Gastric Cancer ◽  
Phase Ii ◽  
Standard Treatment ◽  
Phase Ii Trial ◽  
Distal Gastrectomy ◽  
Sample Size Calculation ◽  
Cox Proportional Hazards Model ◽  
Open Distal Gastrectomy

IntroductionCurrent guidelines recommend open gastrectomy with D2 lymph node dissection and adjuvant chemotherapy as the standard treatment for advanced gastric cancer. However, the prognosis is not satisfactory. Perioperative chemotherapy has been proposed to improve survival. Although still in debate, the efficacy of laparoscopic distal gastrectomy (LDG) in patients with advanced gastric cancer has been demonstrated in a few trials. Therefore, LDG after neoadjuvant chemotherapy can be a candidate for future standard treatment on advanced distal gastric cancer. We propose a randomised phase II trial to compare LDG and open distal gastrectomy (ODG) after neoadjuvant chemotherapy for advanced gastric cancer.Methods and analysisTo test the efficacy and safety, a randomised, open-label, single-centre, phase II trial was designed to evaluate the non-inferiority of LDG compared with ODG after neoadjuvant chemotherapy, with 3-year recurrence-free survival as the primary endpoint. The chosen critical value of a non-inferiority margin was an increase of <8%. The study started in 2015 and enrolled 96 patients according to a prior sample size calculation. Intention-to-treat and per-protocol approach will be used for efficacy analysis, and as-treated analysis will be applied for safety analysis. The survival curves will be constructed as time-to-event plots using the Kaplan-Meier method and compared using log-rank tests and Cox proportional hazards model. All statistical analyses will be conducted in standard statistical software with a significance level of 0.05.Ethics and disseminationThis study was approved by the Peking University Cancer Hospital Ethics Committee. The results will be submitted for publication in peer-reviewed journals.Trial registration numberNCT02404753; Pre-results.

Sign in / Sign up

Export Citation Format

Share Document